PCT, a Caladrius Company, Expands Relationship With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PCT, a Caladrius Company, Expands Relationship With ImmunoCellular Therapeutics to Provide Manufacturing For Their Phase 3 Trial

NEW YORK, June 15, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS ) ("Caladrius"), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today a new Agreement between its wholly-owned subsidiary, PCT, LLC, a Caladrius Company ("PCT"), and ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

Under this Agreement, PCT will produce ICT-107, a dendritic cell-based immunotherapy targeting six glioblastoma tumor-associated antigens, for a pivotal Phase 3 trial in patients with newly diagnosed glioblastoma. PCT has served as an external manufacturing and development provider for ImmunoCellular since 2011, including clinical production for ImmunoCellular's ICT-107 Phase 2 trial.

PCT will provide manufacturing services, including processing, packaging, labelling, quality control testing, release, shipping and storage, as well as process requalification, for ICT-107. The agreement includes the provision of a semi-dedicated controlled environment room and staff to meet ImmunoCellular's Phase 3 manufacturing needs. Furthermore, ImmunoCellular will make use of PCT's capability to perform a technology transfer process to harmonize the EU and US methods of production of ICT-107.

"Ensuring that ImmunoCellular has US manufacturing capacity that can fully support our ICT-107 phase 3 registration program, and potentially include  commercial manufacturing, is an important step toward initiation of our Phase 3 registration program," said Andrew Gengos, ImmunoCellular Chief Executive Officer.

"We are extremely pleased that the leadership team at ImmunoCellular, like a number of our clients, has chosen to develop a long-term relationship partnership with PCT in order to maintain the cell therapy manufacturing reliability, quality, and cost efficiencies they have come to expect," said Dr. Robert A. Preti, President of PCT, and Chief Technology Officer of Caladrius. "We feel our clients significantly reduce their clinical development risk by manufacturing with PCT and leveraging our Innovation and Quality infrastructure."

About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)

Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.  www.caladrius.com

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. Caladrius' actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Caladrius in general, see the factors described under the heading, "Item 1A. Risk Factors" in Caladrius' Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in Caladrius' other periodic filings with the SEC. Caladrius undertakes no obligation to update or revise any forward-looking statements.

Caladrius Biosciences, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 128

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 117

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 102

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 33

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 61

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 134

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 122

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading

Top 5 Most Recently Viewed Articles

Axiom Foods Unveils Neutral Pea Protein Amid Market Challenges

Updated Category News Views 292

Revolutionizing the U.S. Pea Protein Market The U.S. pea protein sector is undergoing significant transformations driven by recent tariff regulations. As steep tariffs were imposed on Chinese imports, the challenges in supply chains have heightened. Axiom Foods is stepping up its game to become a key player in the industry by introducing its innovative product,...

Continue Reading
Cabaletta Bio's Transformative Developments in Autoimmunity Therapy

Updated Category News Views 217

Cabaletta Bio's Progress: A Focus on Innovative Therapies Cabaletta Bio, Inc. (Nasdaq: CABA) is making significant strides in the field of biotechnology, particularly in developing targeted cell therapies for autoimmune diseases. It's clear that the company is gearing up for a transformative journey with rese-cel, an investigational therapy designed to reset the immune...

Continue Reading
NBPE Share Buyback: A Strategic Move for Investors

Updated Category News Views 159

NB Private Equity Partners Announces Strategic Share Buyback In a significant turn of events, NB Private Equity Partners has declared its plans for a share buyback, a move that signals confidence in the company's future and aims to enhance shareholder value. This decision follows the recent approval from shareholders, making it an exciting development for investors...

Continue Reading
New Jersey Welcomes New York Plastic Surgical Group's Expansion

Updated Category News Views 253

New York Plastic Surgical Group Expands to New Jersey New York Plastic Surgical Group (NYPS Group), one of the leading plastic surgery practices in the nation, has announced an exciting expansion into New Jersey. The company has opened a new office in Englewood, providing residents with easy access to its comprehensive range of plastic, reconstructive, and aesthetic...

Continue Reading
Huasun Energy Expands Presence with Next2Sun Partnership in PV Tech

Updated Category News Views 416

Huasun Energy and Next2Sun Forge Exclusive Partnership Huasun Energy, recognized globally as the leading producer of heterojunction (HJT) solar products, has entered into an exclusive strategic partnership with Next2Sun, a notable player in vertical solar technology. This collaboration marks an important advancement for the integration of vertical photovoltaic (PV)...

Continue Reading